---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-22-000163"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T04:59:13.876660+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics appoints David Perez to board, Warren Stone as clinical services president

## Summary
- David B. Perez appointed to Board effective Nov 3, 2022; term until 2023 annual meeting.
- Warren Stone appointed President, Clinical Services Division effective Nov 21, 2022, replacing Dr. David Sholehvar.
- Stone's compensation: $525K base, 50% target bonus, $1M annual equity, $350K sign-on cash, $2M sign-on equity, $250K relocation.
- Perez is former Terumo BCT CEO; brings 40 years of global executive leadership experience in medical devices and healthcare.

## SEC filing metadata
- accession: 0001077183-22-000163
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/0001077183-22-000163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/neo-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-22-000163
- JSON: https://secwatch.observer/filing/0001077183-22-000163.json
- Plain text: https://secwatch.observer/filing/0001077183-22-000163.txt

## Key facts
- Executive change
  David B. Perez was appointed as Director at NEOGENOMICS INC.
  - Action: appointed
  - Role: Director
  source text: Effective November 3, 2022, the Board of Directors (the “Board”) of NeoGenomics, Inc., a Nevada corporation (the “Company”), appointed David B. Perez to serve as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/0001077183-22-000163-index.htm
- Executive change
  Dr. David Sholehvar departed as President, Clinical Services Division at NEOGENOMICS INC.
  - Action: departed
  - Role: President, Clinical Services Division
  source text: The Company's former President, Clinical Services Division, Dr. David Sholehvar’s last day at the Company was November 4, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/0001077183-22-000163-index.htm
- Executive change
  Warren Stone was appointed as President, Clinical Services Division at NEOGENOMICS INC.
  - Action: appointed
  - Role: President, Clinical Services Division
  source text: On November 2, 2022, the Company appointed Warren Stone, age 50, President, Clinical Services Division of the Company, effective November 21, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/0001077183-22-000163-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.